Overview

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Status:
Not yet recruiting

Trial end date:
2023-03-28

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:

Phase:

Phase 3

Details

Lead Sponsor:

Bausch & Lomb Incorporated

Treatments:

Brimonidine Tartrate
Ketotifen
Ophthalmic Solutions
Pharmaceutical Solutions